metaEvidence - overview


			Statistically conclusive or suggested result	Inconclusive results	Uncertain results	Safety results
multiple myeloma - 2nd line (L2) multiple myeloma - 2nd line (L2)
versus pomalidomide and dexamethasone
	pembrolizumab plus pomalidomide and dexamethasone vs. pomalidomide and dexamethasone	1	none	inconclusive results for: DCR; DOR; objective responses (ORR); AE (any grade); AE (grade 3-4); AE leading to death (grade 5); SAE (any grade); Hepatitis TRAE (grade 3-4); Hyperthyroidism TRAE (grade 3-4); Hypothyroidism TRAE (grade 3-4); Infusion-related reactions TRAE (grade 3-4); Myocarditis TRAE (grade 3-4); Pneumonitis TRAE (grade 3-4); Rash TRAE (grade 3-4); Stevens-Johnson syndrome TRAE (grade 3-4); Anaemia AE (grade 3-4); Asthenia AE (grade 3-4); Back pain AE (grade 3-4); Constipation AE (grade 3-4); Cough AE (grade 3-4); Diarrhoea AE (grade 3-4); Dizziness AE (grade 3-4); Dyspnoea AE (grade 3-4); Headache AE (grade 3-4); Increased ALT AE (grade 3-4); Nausea AE (grade 3-4); Neutropenia AE (grade 3-4); Peripheral oedema AE (grade 3-4); Pneumonia AE (grade 3-4); Pyrexia AE (grade 3-4); Thrombocytopenia AE (grade 3-4)	suggested 95 % decrease in Fatigue AE (grade 3-4) but the degree if certainty is unassessable	61 % increase in deaths (OS) with safety concern statistically significant harm 53 % increase in progression or deaths (PFS) with safety concern